Skip to main navigation
Menu
  • Focus & Strategy
  • Innovation & Pipeline
  • Disease Areas
  • Investors & Media
  • Contact
Focus & Strategy
  • President’s Letter
  • Leadership
  • Board of Directors
Innovation & Pipeline
  • Roluperidone (MIN-101)
  • Seltorexant (MIN-202)
  • MIN-301
Disease Areas
  • Schizophrenia
  • Insomnia and Mood Disorders
  • Parkinson’s Disease
Investors & Media
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us
Corporate Governance
  • Executive Management
  • Board of Directors
  • Committee Composition
  • Contact the Board
Financials & Filings
  • SEC Filings
  • Annual Reports and Proxies
  • Quarterly Results
  • Key Ratios
Stock Information
  • Historic Stock Lookup
  • Investment Calculator
  • Analyst Coverage
Minerva Neurosciences logo
  • Focus & Strategy
    • President’s Letter
    • Leadership
    • Board of Directors
  • Innovation & Pipeline
    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • Disease Areas
    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact Us
  • Contact

INVESTORS & MEDIA

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
    • Form 8937
  • Stock Information
  • Investor FAQs
  • Contact Us

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS

Annual Reports and Proxies

Form 10-Ks

Filing date View
Mar 01, 2022 View HTML
0001564590-22-007853.pdf
0001564590-22-007853.rtf
0001564590-22-007853.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Mar 08, 2021 View HTML
0001564590-21-011340.pdf
0001564590-21-011340.rtf
0001564590-21-011340.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Mar 09, 2020 View HTML
0001564590-20-009243.pdf
0001564590-20-009243.rtf
0001564590-20-009243.xls
EX-101.INS - XBRL INSTANCE DOCUMENT

Proxy Statements

Filing date View
Apr 26, 2022 View HTML
0001193125-22-120328.pdf
0001193125-22-120328.rtf
0001193125-22-120328.xls
Apr 26, 2022 View HTML
0001193125-22-120341.pdf
0001193125-22-120341.rtf
0001193125-22-120341.xls
Apr 14, 2022 View HTML
0001193125-22-105549.pdf
0001193125-22-105549.rtf
0001193125-22-105549.xls

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS
  • About Us

    • President's Letter
    • Leadership
    • Board of Directors
  • Disease Areas

    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Innovation & Pipeline

    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • (617) 600-7373
    email us
    Privacy Policy | Terms of Use

    Biotech Web Design Company ©2017 Minerva Neurosciences